Herpes Simplex Dendritic Keratitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for herpes simplex dendritic keratitis. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
1
Active US patents
42/100
Avg vulnerability
—
Annual revenue covered

Originators in Herpes Simplex Dendritic Keratitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Roche Palo 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating herpes simplex dendritic keratitis. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytovene
GANCICLOVIR
 Roche Palo 1 42 — 2034-09-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9486530 Cytovene formulation 42 2034-09-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9486530 Cytovene formulation 42 2034-09-02

Related